11:44:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-30 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2023-12-04 Kvartalsrapport 2024-Q2
2023-10-04 Ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 Årsstämma 2024
2023-08-31 Kvartalsrapport 2024-Q1
2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Årsstämma 2019
2018-09-24 Kvartalsrapport 2019-Q1
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Årsstämma 2018
2017-09-25 Kvartalsrapport 2018-Q1
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2023-03-01 08:45:00

Mölndal, Sweden, March 1[st] , 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Shirley Ryan AbilityLab - a top-ranked physical medicine and rehabilitation hospital based in Chicago, US - has received a USD 1.5 million grant from the US Department of Defense. The grant will finance a clinical trial to examine the benefits (function, biomechanics, metabolics and user satisfaction) of Integrum's OPRA[TM] Implant System compared to a traditional socket prosthesis system in three individuals with lower-limb amputations.

Shirley Ryan AbilityLab is a global leader in the field of bionics - the study of mechanical systems that mimic parts of living organisms. The US Department of Defense grant, provided through the US Army's Congressionally Directed Medical Research Program (CDMRP), will be financing the first clinical program in the world combining osseointegration, targeted muscle reinnervation (TMR), and pattern-recognition control to operate a fully powered bionic leg prosthesis, using electromyographic (EMG) sensors.

The clinical study aims to evaluate the comfort and function of Integrum's OPRA[TM][ ]Implant System compared to socked-based technologies in patients with transfemoral amputations who have received TMR and ambulate with a powered leg prosthesis. Integrum will supply OPRA[TM] implant systems to Shirley Ryan AbilityLab and surgeons at Northwestern Medicine will implant the devices and perform the TMR surgeries.

"The US Department of Defense grant rewarded to Shirley Ryan AbilityLab is a significant recognition, pointing toward the potential of Integrum's OPRA[TM] Implant System. We are looking forward to contributing to this important initiative that aims to validate our groundbreaking technology and thereby take it yet another step towards the next generation of body-integrated solutions," comments Rickard Brånemark, CEO of Integrum.